CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2024年4月20日～2024年5月3日の間に収集した論文情報を追加しました。

  1. Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance.

  MET選択的TKIに関連する有害事象の重要性を強調

  対象DB：FAERS

  2. Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system.

  エラゴリクスの安全性と新たな副作用シグナルを解析

  対象DB：FAERS

  3. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.

  FAERSを用いた抗体薬物複合体の副作用の優先度付け

  対象DB：FAERS

  4. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.

  FDAの承認を受けた抗体薬物複合体の副作用をFAERSから評価

  対象DB：FAERS

  5. Prolonged Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Postmarketing Cases.

  SGLT2阻害剤治療中の2型糖尿病患者における持続的または再発性ケトアシドーシスの報告事例

  対象DB：FAERS

  6. Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure.

  DDIの時間的妥当性を考慮した不均衡性シグナルの優先順位付け方法を開発

  対象DB：FAERS

  7. Comparison of safety of acetaminophen and ibuprofen in minors: based on the FAERS database.

  18歳未満の患者におけるパラセタモールとイブプロフェンの有害事象を調査

  対象DB：FAERS

  8. A real-world disproportionality analysis of FDA adverse event reporting system events for ibuprofen.

  イブプロフェンの重要な有害事象を分析

  対象DB：FAERS

  9. Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system.

  ベンダムスチンの有害事象を分析

  対象DB：FAERS

  10. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.

  FDA承認のがん治療用生物学的製剤のバイオシミラーの安全性を比較

  対象DB：FAERS

  11. Rising cases of drug-induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000-2022.

  FAERSを用いた23年間の肺線維症の解析

  対象DB：FAERS

  12. Phosphodiesterase type 5 inhibitors related hearing impairment: a real world study based on the FDA adverse event reporting system.

  PDE5阻害剤に関連した聴覚障害の分析

  対象DB：FAERS

  13. Blind Spots in Therapy: Unveiling Drug-Induced Angle-Closure Glaucoma Through a National Analysis.

  FAERSを用いた、閉塞隅角緑内障を引き起こす医薬品の特定と量的評価

  対象DB：FAERS

  14. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.

  エスシタロプラムオキサレートの潜在的有害事象をFAERSから多次元的に評価

  対象DB：FAERS

  15. A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.

  コリスチンとポリミキシンBの有害事象を比較

  対象DB：FAERS

  16. Analysis of Inclisiran in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and Sex-specific Subgroups.

  FAERSデータからインクリシランの有害事象を分析

  対象DB：FAERS

  17. A Comparison of Currently Approved Small Interfering RNA (siRNA) Medications to Alternative Treatments by Costs, Indications, and Medicaid Coverage.

  siRNA薬の現状と課題。高コストやアクセスの制約など

  対象DB：FAERS

  18. Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS.

  COVID-19ワクチンとてんかん発作の関連性を検討

  対象DB：FAERS,VAERS

  19. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.

  アミバンタマブの心血管毒性の調査

  対象DB：FAERS

  20. Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.

  インフルエンザ治療薬の使用と消化管出血の関連性を検証

  対象DB：FAERS

  21. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.

  FAERSにおけるチカグレロールの副作用の分析

  対象DB：FAERS

  22. The association between the adverse event reporting system and burnout and job satisfaction of nurses: Workplace violence as a mediator.

  精神科看護師の仕事満足度と職業倦怠感と、AERS導入の影響

  対象DB：FAERS

  23. JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022-2023.

  JYNNEOSワクチンの安全性調査結果は、予期せぬ安全性上の懸念はないことを示唆

  対象DB：FAERS,VAERS

  24. Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review.

  GO治療中にCD33陽性マクロファージの破壊が起こり、フリーヘモグロビンの蓄積を引き起こす可能性

  対象DB：FAERS

  25. Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER.

  バンコマイシンとピペラシリン・タゾバクタムの併用はAKIの発生率を増加させる可能性

  対象DB：JADER

  26. Time-to-onset Analysis of Rhabdomyolysis due to Different Proton Pump Inhibitors Using a Pharmacovigilance Database.

  PPIの使用と横紋筋融解症との関連を評価

  対象DB：JADER

  27. View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences.

  メトホルミンは広く使用されており、その薬理学的および薬物動態学的研究が継続されている

  対象DB：EudraVigilance,VigiBase

  28. Development, assessment and educational impact of a blended e-learning training program on pharmacovigilance implemented in four African countries.

  PAVIAプロジェクトのトレーニングプログラムは効果的で、医療従事者の知識向上と報告率の増加に貢献

  対象DB：VigiBase

  29. Association between Direct Acting Agents used for chronic hepatitis C virus infection and the occurrence of acute leukaemia - A disproportionality analysis.

  HCV感染患者でのDAA使用とAMLの関連性についての研究

  対象DB：VigiBase

  30. Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis.

  小児SJS-TENに関連する薬剤のスペクトルをVigiBaseから調査

  対象DB：VigiBase

  31. Dental Adverse Effects of Anti-CD20 Therapies.

  抗CD20療法中に歯科疾患が報告

  対象DB：VigiBase

  32. Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer.

  VigiBaseを用いた抗体薬物複合体（ADC）治療に関連した有害事象を評価

  対象DB：VigiBase

  33. Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.

  日本の患者でのペムブロリズマブによる心臓関連の有害事象の発生率と特徴を調査

  対象DB：JADER

  34. Analysis of in-hospital deaths in patients with critical limb ischemia necessitating invasive treatments: based on a Japanese nationwide database.

  日本のCLI患者の入院死亡率とその原因を調査

  対象DB：DPC

  35. Development and validation of a machine learning model to predict postoperative delirium using a nationwide database: A retrospective, observational study.

  手術後のせん妄を予測する機械学習モデルの開発・検証

  対象DB：DPC

  36. Complications after peripherally inserted central catheter versus central venous catheter implantation in intensive care unit: propensity score analysis using a nationwide database.

  日本の入院患者でのCVCとPICCの比較では、PICCグループの合併症の発生率が高い

  対象DB：DPC

  37. Trends in the prevalence and incidence of Crohn's disease in Japan and the United States.

  日米のクローン病の発生率には差がある

  対象DB：JMDC

  38. Cost-effectiveness analysis of transcatheter aortic valve implantation in aortic stenosis patients at low- and intermediate-surgical risk in Japan.

  TAVIは低・中等リスク患者においてSAVRより費用対効果が高い

  対象DB：MDV

  39. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population-based cohort study.

  SU剤を使用する患者において、フルオロキノロンは重度低血糖リスクを増加させない可能性

  対象DB：CPRD

  40. Risk factors for asthma-related hospital and intensive care admissions in children, adolescents and adults: a cohort study using primary and secondary care data.

  喘息患者の入院率には、年齢、性別、民族性、および医薬品使用量などの要因が関連

  対象DB：CPRD

  41. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study.

  イディオパシック肺線維症の発生率と死亡率が増大している可能性

  対象DB：CPRD

  42. Risk of bleeding amongst warfarin and direct oral anticoagulant users prescribed immediate antibiotics for respiratory tract infection: Cohort study.

  RTI患者での抗生物質の即時使用は、出血リスクを低減する可能性

  対象DB：CPRD

  43. Association of ethnicity and socioeconomic status with health outcomes in women with gestational diabetes: Clinical practice research datalink cohort study.

  妊娠糖尿病既往者の健康合併症のリスクは、民族性と社会経済的地位によって異なる可能性

  対象DB：CPRD

  44. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.

  GLP-1受容体作動薬とSGLT-2阻害薬の併用は、心血管イベントや腎イベントのリスクを減少させる可能性

  対象DB：CPRD

  45. Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study.

  ガバペンチノイドの処方は、薬物乱用や過剰摂取のリスクが高い可能性

  対象DB：CPRD

  46. The long-term impact of vaginal surgical mesh devices on pain clinic and psychological service referrals, anti-inflammatory testing and pelvic scans in UK primary care: A cohort study with the Clinical Practice Research Datalink.

  SUI/POP手術後の女性は、追加の医療が必要な可能性が高い

  対象DB：CPRD

  47. Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan.

  頭痛で医療を受ける患者は、頭痛が頻繁でQOLが低い傾向

  対象DB：DeSC

  48. Effect of COVID-19 Infection on Presenteeism: Cohort Study Using Large Health Insurance-Based Data in Japan.

  COVID-19感染者は、仕事中の健康問題が悪化しやすい傾向にある可能性

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み